Review article: gastrointestinal features in COVID‐19 and the possibility of faecal transmission

• Published in: Alimentary pharmacology & therapeutics Vol. 51; no. 9; pp. 843 - 851
• Main Authors: Tian, Yuan, Rong, Long, Nian, Weidong, He, Yan
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.05.2020; John Wiley and Sons Inc
• Subjects: ACE2; Adult; Angiotensin; Angiotensin-converting enzyme 2; Anorexia; Betacoronavirus; Case reports; Child; Children; China - epidemiology; Coronavirus Infections - complications; Coronavirus Infections - epidemiology; Coronavirus Infections - transmission; COVID-19; Diarrhea; Diarrhea - epidemiology; Diarrhea - virology; Disease Outbreaks; Epidemics; Epithelial cells; Excretion; Feces; Feces - virology; Gastrointestinal Diseases - epidemiology; Gastrointestinal Diseases - virology; Humans; Incidence; Nausea; Nucleocapsids; Pain; Pandemics; Peptidyl-dipeptidase A; Pneumonia, Viral - complications; Pneumonia, Viral - epidemiology; Pneumonia, Viral - transmission; Review; SARS-CoV-2; Sputum; Vomiting; Vomiting - epidemiology; Vomiting - virology; China
• ISSN: 0269-2813; 1365-2036; 1365-2036
• DOI: 10.1111/apt.15731

Summary Background There is little published evidence on the gastrointestinal features of COVID‐19. Aims To report on the gastrointestinal manifestations and pathological findings of patients with COVID‐19, and to discuss the possibility of faecal transmission. Methods We have reviewed gastrointestinal features of, and faecal test results in, COVID‐19 from case reports and retrospective clinical studies relating to the digestive system published since the outbreak. Results With an incidence of 3% (1/41)‐79% (159/201), gastrointestinal symptoms of COVID‐19 included anorexia 39.9% (55/138)‐50.2% (101/201), diarrhoea 2% (2/99)‐49.5% (146/295), vomiting 3.6% (5/138)‐66.7% (4/6), nausea 1% (1/99)‐29.4% (59/201), abdominal pain 2.2% (3/138)‐6.0% (12/201) and gastrointestinal bleeding 4% (2/52)‐13.7% (10/73). Diarrhoea was the most common gastrointestinal symptom in children and adults, with a mean duration of 4.1 ± 2.5 days, and was observed before and after diagnosis. Vomiting was more prominent in children. About 3.6% (5/138)‐15.9% (32/201) of adult and 6.5% (2/31)‐66.7% (4/6) of children patients presented vomiting. Adult and children patients can present with digestive symptoms in the absence of respiratory symptoms. The incidence of digestive manifestations was higher in the later than in the early stage of the epidemic, but no differences in digestive symptoms among different regions were found. Among the group of patients with a higher proportion of severe cases, the proportion of gastrointestinal symptoms in severe patients was higher than that in nonsevere patients (anorexia 66.7% vs 30.4%; abdominal pain 8.3% vs 0%); while in the group of patients with a lower severe rate, the proportion with gastrointestinal symptoms was similar in severe and nonsevere cases (nausea and vomiting 6.9% vs 4.6%; diarrhoea 5.8% vs 3.5%). Angiotensin converting enzyme 2 and virus nucleocapsid protein were detected in gastrointestinal epithelial cells, and infectious virus particles were isolated from faeces. Faecal PCR testing was as accurate as respiratory specimen PCR detection. In 36% (5/14)‐53% (39/73) faecal PCR became positive, 2‐5 days later than sputum PCR positive. Faecal excretion persisted after sputum excretion in 23% (17/73)‐82% (54/66) patients for 1‐11 days. Conclusions Gastrointestinal symptoms are common in patients with COVID‐19, and had an increased prevalence in the later stage of the recent epidemic in China. SARS‐CoV‐2 enters gastrointestinal epithelial cells, and the faeces of COVID‐19 patients are potentially infectious.